- Home
- TRML vs SOR Comparison
TRML vs SOR Comparison
Compare TRML & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- SOR
- Stock Information
- Founded
- TRML 2021
- SOR 1968
- Country
- TRML United States
- SOR United States
- Employees
- TRML N/A
- SOR N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- TRML Health Care
- SOR Finance
- Exchange
- TRML Nasdaq
- SOR Nasdaq
- Market Cap
- TRML 419.1M
- SOR 361.3M
- IPO Year
- TRML N/A
- SOR N/A
- Fundamental
- Price
- TRML $27.66
- SOR $45.39
- Analyst Decision
- TRML Strong Buy
- SOR
- Analyst Count
- TRML 3
- SOR 0
- Target Price
- TRML $64.67
- SOR N/A
- AVG Volume (30 Days)
- TRML 202.3K
- SOR 16.2K
- Earning Date
- TRML 11-07-2024
- SOR 01-01-0001
- Dividend Yield
- TRML N/A
- SOR 7.24%
- EPS Growth
- TRML N/A
- SOR N/A
- EPS
- TRML N/A
- SOR 6.50
- Revenue
- TRML N/A
- SOR N/A
- Revenue This Year
- TRML N/A
- SOR N/A
- Revenue Next Year
- TRML N/A
- SOR N/A
- P/E Ratio
- TRML N/A
- SOR $6.41
- Revenue Growth
- TRML N/A
- SOR N/A
- 52 Week Low
- TRML $12.12
- SOR $36.41
- 52 Week High
- TRML $48.31
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- TRML 58.78
- SOR 71.41
- Support Level
- TRML $25.10
- SOR $43.71
- Resistance Level
- TRML $28.35
- SOR $45.50
- Average True Range (ATR)
- TRML 1.37
- SOR 0.60
- MACD
- TRML -0.26
- SOR 0.16
- Stochastic Oscillator
- TRML 57.98
- SOR 94.40
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.